By Deena Beasley
July 29 (Reuters) - Gilead Sciences Inc GILD.O on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.
Total revenue for the quarter rose 21% from a year earlier to $6.2 billion, slightly higher than the average analyst estimate of $6.07 billion as compiled by Refinitiv.
Sales of the company's flagship HIV medicines, which have stalled during the coronavirus pandemic, fell 2% to $3.9 billion.
Gilead reported adjusted quarterly earnings of $1.87 per share, beating the average Wall Street estimate of $1.75 per share.
Sales of Veklury, known chemically as remdesivir, totaled $829 million for the quarter, easily beating Wall Street estimates of $675 million. Gilead said Veklury sales would continue to be subject to uncertainty since they are tightly linked to COVID-19 hospitalization rates.
For full-year 2021, Gilead narrowed its forecast for adjusted earnings per share to $6.90 to $7.25 from its prior projection of $6.75 to $7.45.
The company said it now expects product sales for the year of $24.4 billion to $25 billion, compared with a previous estimate of $23.7 billion to $25.1 billion.
(Reporting By Deena Beasley Editing by Bill Berkrot)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.